Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 274

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Development of a Multimarker Assay for Early Detection of Ovarian Cancer

Open access
Yurkovetsky, Zoya, Skates, Steven, Lomakin, Aleksey, Nolen, Brian, Pulsipher, Trenton, Modugno, Francesmary, Marks, Jeffrey, Godwin, Andrew, Gorelik, Elieser, Jacobs, Ian, Menon, Usha, Lu, Karen, Badgwell, Donna, Bast, Robert C., Lokshin, Anna E. · 2010 · Journal of Clinical Oncology

Abstract

Purpose: Early detection of ovarian cancer has great promise to improve clinical outcome. Patients and Methods: Ninety-six serum biomarkers were analyzed in sera from healthy women and from patients with ovarian cancer, benign pelvic tumors, and breast, colorectal, and lung cancers, using multiplex xMAP bead-based immunoassays. A Metropolis algorithm with Monte Carlo simulation (MMC) was used for analysis of the data. Results: A training set, including sera from 139 patients with early-stage ovarian cancer, 149 patients with late-stage ovarian cancer, and 1,102 healthy women, was analyzed with MMC algorithm and cross validation to identify an optimal biomarker panel discriminating early-stage cancer from healthy controls. The four-biomarker panel providing the highest diagnostic power of 86% sensitivity (SN) for early-stage and 93% SN for late-stage ovarian cancer at 98% specificity (SP) was comprised of CA-125, HE4, CEA, and VCAM-1. This model was applied to an independent blinded validation set consisting of sera from 44 patients with early-stage ovarian cancer, 124 patients with late-stage ovarian cancer, and 929 healthy women, providing unbiased estimates of 86% SN for stage I and II and 95% SN for stage III and IV disease at 98% SP. This panel was selective for ovarian cancer showing SN of 33% for benign pelvic disease, SN of 6% for breast cancer, SN of 0% for colorectal cancer, and SN of 36% for lung cancer. Conclusion: A panel of CA-125, HE4, CEA, and VCAM-1, after additional validation, could serve as an initial stage in a screening strategy for epithelial ovarian cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.19.2484

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 274

Metadata

Authors
Yurkovetsky, Z., Skates, S., Lomakin, A., Nolen, B., Pulsipher, T., Modugno, F., Marks, J., Godwin, A., Gorelik, E., Jacobs, I., Menon, U., Lu, K., Badgwell, D., Bast, R. C., & Lokshin, A. E.
Venue
Journal of Clinical Oncology
Published
2010-05-01
Volume
28
Issue
13
Pages
2159-2166
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2145803449
Cited by
274
References
55
FWCI
35.15
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of a Multimarker Assay for Early Detection of Ovarian Cancer. https://app.cochat.ai/papers/10.1200/jco.2008.19.2484
The paper
Yurkovetsky, Z., Skates, S., Lomakin, A., Nolen, B., Pulsipher, T., Modugno, F., Marks, J., Godwin, A., Gorelik, E., Jacobs, I., Menon, U., Lu, K., Badgwell, D., Bast, R. C., & Lokshin, A. E. (2010). Development of a Multimarker Assay for Early Detection of Ovarian Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.19.2484

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.